-DOCSTART- -X- O
Here -X- _ O
, -X- _ O
we -X- _ O
report -X- _ O
the -X- _ O
anti-human -X- _ O
immunodeficiency -X- _ O
virus -X- _ O
( -X- _ O
HIV -X- _ O
) -X- _ O
potency -X- _ O
and -X- _ O
underlying -X- _ O
mechanisms -X- _ O
of -X- _ O
a -X- _ O
Keggin -X- _ B-Intervention
polyoxometalate -X- _ I-Intervention
( -X- _ I-Intervention
PT-1 -X- _ I-Intervention
, -X- _ I-Intervention
K -X- _ I-Intervention
( -X- _ I-Intervention
6 -X- _ I-Intervention
) -X- _ I-Intervention
HPTi -X- _ I-Intervention
( -X- _ I-Intervention
2 -X- _ I-Intervention
) -X- _ I-Intervention
W -X- _ I-Intervention
( -X- _ I-Intervention
10 -X- _ I-Intervention
) -X- _ I-Intervention
O -X- _ I-Intervention
( -X- _ I-Intervention
40 -X- _ I-Intervention
) -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
Our -X- _ O
findings -X- _ O
showed -X- _ O
that -X- _ O
PT-1 -X- _ B-Outcome
exhibited -X- _ I-Outcome
highly -X- _ I-Outcome
potent -X- _ I-Outcome
effects -X- _ I-Outcome
against -X- _ I-Outcome
a -X- _ I-Outcome
diverse -X- _ I-Outcome
group -X- _ I-Outcome
of -X- _ I-Outcome
HIV -X- _ I-Outcome
type -X- _ I-Outcome
1 -X- _ I-Outcome
( -X- _ I-Outcome
HIV-1 -X- _ I-Outcome
) -X- _ I-Outcome
strains -X- _ I-Outcome
and -X- _ I-Outcome
displayed -X- _ I-Outcome
low -X- _ I-Outcome
cytotoxicity -X- _ I-Outcome
and -X- _ I-Outcome
genotoxicity. -X- _ I-Outcome
The -X- _ I-Outcome
time-addition -X- _ I-Outcome
assay -X- _ I-Outcome
revealed -X- _ I-Outcome
that -X- _ I-Outcome
PT-1 -X- _ I-Outcome
acted -X- _ I-Outcome
at -X- _ I-Outcome
an -X- _ I-Outcome
early -X- _ I-Outcome
stage -X- _ I-Outcome
of -X- _ I-Outcome
infection -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
these -X- _ I-Outcome
findings -X- _ I-Outcome
were -X- _ I-Outcome
supported -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
observation -X- _ I-Outcome
that -X- _ I-Outcome
PT-1 -X- _ I-Outcome
had -X- _ I-Outcome
more -X- _ I-Outcome
potency -X- _ I-Outcome
against -X- _ I-Outcome
Env-pseudotyped -X- _ I-Outcome
virus -X- _ I-Outcome
than -X- _ I-Outcome
vesicular -X- _ I-Outcome
stomatitis -X- _ I-Outcome
virus -X- _ I-Outcome
glycoprotein -X- _ I-Outcome
( -X- _ I-Outcome
VSVG -X- _ I-Outcome
) -X- _ I-Outcome
pseudotyped -X- _ I-Outcome
virus. -X- _ I-Outcome
Surface -X- _ I-Outcome
plasmon -X- _ I-Outcome
resonance -X- _ I-Outcome
binding -X- _ I-Outcome
assays -X- _ I-Outcome
and -X- _ I-Outcome
flow -X- _ I-Outcome
cytometry -X- _ I-Outcome
analysis -X- _ I-Outcome
showed -X- _ I-Outcome
that -X- _ I-Outcome
PT-1 -X- _ I-Outcome
blocked -X- _ I-Outcome
the -X- _ I-Outcome
gp120 -X- _ I-Outcome
binding -X- _ I-Outcome
site -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
CD4 -X- _ I-Outcome
receptor. -X- _ I-Outcome
Moreover -X- _ I-Outcome
, -X- _ I-Outcome
PT-1 -X- _ I-Outcome
bound -X- _ I-Outcome
directly -X- _ I-Outcome
to -X- _ I-Outcome
gp41 -X- _ I-Outcome
NHR -X- _ I-Outcome
( -X- _ I-Outcome
N36 -X- _ I-Outcome
peptide -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
thereby -X- _ I-Outcome
interrupting -X- _ I-Outcome
the -X- _ I-Outcome
core -X- _ I-Outcome
bundle -X- _ I-Outcome
formation -X- _ I-Outcome
of -X- _ I-Outcome
gp41. -X- _ I-Outcome
In -X- _ O
conclusion -X- _ O
, -X- _ O
our -X- _ O
data -X- _ O
suggested -X- _ O
that -X- _ O
PT-1 -X- _ O
may -X- _ O
be -X- _ O
developed -X- _ O
as -X- _ O
a -X- _ O
new -X- _ O
anti-HIV-1 -X- _ O
agent -X- _ O
through -X- _ O
its -X- _ O
effects -X- _ O
on -X- _ O
entry -X- _ O
inhibition -X- _ O
. -X- _ O

